Roche Enters $7.1 Billion Deal to Acquire Telavant
Swiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreSwiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreThe MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read moreAccording to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read moreMyMD Pharmaceuticals, Inc.®, a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreTezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read morePfizer has reported that the Japanese Ministry of Health, Labour and Welfare (MHLW) authorized CIBINQO® (abrocitinib), a novel therapy for
Read moreEctica Technologies is delighted to announce it will be presenting as a corporate sponsor at the upcoming CHI Conference on
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read more